BlackRock Group LTD - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 14 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Group LTD ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2016$229,000
-22.9%
100,711
-7.8%
0.00%
Q2 2016$297,000
-30.9%
109,186
-27.2%
0.00%
Q1 2016$430,000
-42.5%
149,969
-12.6%
0.00%
Q4 2015$748,000
-42.8%
171,6000.0%0.00%
-100.0%
Q3 2015$1,308,000
-31.6%
171,6000.0%0.00%0.0%
Q2 2015$1,913,000171,6000.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2016
NameSharesValueWeighting ↓
PERKINS CAPITAL MANAGEMENT INC 2,426,300$802,0000.74%
Cowen Prime Services LLC 1,411,500$466,0000.23%
GSA CAPITAL PARTNERS LLP 1,205,873$398,0000.07%
Nantahala Capital Management 5,113,958$1,690,0000.05%
HighMark Wealth Management LLC 80,000$26,0000.02%
Kalos Management, Inc. 72,858$24,0000.01%
Qube Research & Technologies Ltd 585,187$193,0000.00%
WINTON GROUP Ltd 190,146$63,0000.00%
Ironwood Financial, llc 1,571$1,0000.00%
Virtu Financial LLC 12,049$4,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders